Quotables
"What, sir, would you make a ship sail against the wind and currents by lighting a bonfire under her deck? I pray you, excuse me, I have not the time to listen to such nonsense."
Napoleon Bonaparte ; When told of the Robert Fulton steamboat
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8044100 | Methods and compositions for treating amyloid-related diseases Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. ... | 10/25/2011 |
| 7705051 | Therapeutical agent useful for the treatment of plasma cell neoplasias The use of calcium trifluoroacetate for the preparation of a drug for the treatment of plasma cell neoplasias, particularly multiple myeloma. ... | 04/27/2010 |
| 7560490 | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavoring agent; and purified water... | 07/14/2009 |
| 7368440 | Methods for the administration of amifostine and related compounds The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compound... | 05/06/2008 |
| 7351736 | Therapeutic compositions (II) Method of producing a physiologically acceptable ketosis such as to treat a patient in need of therapy for one or more of Amylotrophic lateral sclerosis, Free Radical disease, Heart failure and Duchenne's muscular dystrophy by oral administration to the patient of a... | 04/01/2008 |
| 7309721 | Aminoalkylphosphonates and related compounds as Edg receptor agonists The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejecti... | 12/18/2007 |
| 7309719 | Stabilized pharmaceutical preparation of gamma-aminobutyric acid derivatives and process for preparing the same The present invention provides a stabilized pharmaceutical preparation of a 4-amino-3-substituted-butanoic acid derivative which can be obtained by incorporating an amino acid as a stabilizer. ... | 12/18/2007 |
| 7307103 | Sodium dodecyl sulfate compositions for inactivating prions An antiseptic composition useful in destroying the infectivity of infectious proteins such as prions is disclosed. The antiseptic composition is preferably maintained at either a low pH of 4.0 or less or a high pH of 10.0 or more either of which allows for an enviro... | 12/11/2007 |
| 7291599 | Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases The invention relates to a process for the treatment of neurodegenerative diseases wherein mis-folded proteins accumulate in characteristic lesions and contribute substantially to a pathogenesis and to an inflammatory reaction magnifying the damage, by the isolated ... | 11/06/2007 |
| 7276535 | Intratesticular injection of chemical sterilant A low effective dose of a biologically acceptable chemical sterilant is injected into the dorsal cranial portion of a scrotal testis of a male animal for the purpose effecting sterilization of the animal. The injection of the chemical sterilant into the dorsal crani... | 10/02/2007 |
| 7255882 | Enkephalinase inhibitor and GABA precursor loading as anti-anxiety compositions Benzodiazepine withdrawal induced anxiety is treated by administration of an enkephalinase inhibitor, and a gamma-aminobutyric acid (“GABA”) precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter functi... | 08/14/2007 |
| 7238718 | Method for treating myolytic disease and method for screening antimyolytic agent An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic pros... | 07/03/2007 |
| 7229969 | Combinations of enzyme inhibitors and the use thereof Combination of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (... | 06/12/2007 |
| 7223736 | Composition for the prevention and treatment of cachexia The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of ω-3 fatty acids such as alpha-linoleni... | 05/29/2007 |
| 7205435 | Type B botulism toxin inhibitors Novel compounds of general formula (I), are provided with inhibitory properties for the type B botulism toxin activity, along with methods for preparation thereof and corresponding pharmaceutical compositions. ... | 04/17/2007 |
| 7184825 | Needless medical connector having antimicrobial agent A needleless connector for medical use, adapted to facilitate the flow of fluid therethrough, includes a housing having an inlet port and an outlet port. The connector also includes a flex-tube assembly defining a fluid path between the inlet port and the outlet por... | 02/27/2007 |
| 7176192 | Method for treating patients for radiation exposure This invention relates to a method of treating a patient suffering from ionizing radiation exposure, or of treating a patient about to undergo ionizing radiation therapy. The method includes administering to a patient in need of treatment an effective amount of a th... | 02/13/2007 |
| 7105575 | Methods for the treatment of neuro- disorders using aminothiol compounds The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the inve... | 09/12/2006 |
| 7060670 | Stereoselective antifibrillogenic peptides and peptidomimetics thereof The present invention relates to antifibrillogenic agents for inhibiting amyloidosis and/or for cytoprotection for the treatment amyloidosis disorders. These agents include peptides, isomers thereof and peptidomimetic compounds thereof. These agents comprise peptide... | 06/13/2006 |
| 7053072 | Methods for the administration of amifostine and related compounds The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared wi... | 05/30/2006 |
| 7048951 | Systems and methods for topical treatment with nitric oxide A simple, biocompatible system and procedure for generating nitric oxide (NO) is described. A mixture of powdered sodium nitrite, ascorbic acid, and maleic acid (or another organic acid of adequate strength) immediately generates nitric oxide (NO) on treatment with ... | 05/23/2006 |
| 7029703 | Composition for promoting healthy bone structure A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, f... | 04/18/2006 |
| RE39049 | Methods for inhibiting bone loss The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptab... | 03/28/2006 |
| 7019031 | Anticancer agents based on regulation of protein prenylation Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g.... | 03/28/2006 |
| 7011855 | Biochemically balanced peritoneal dialysis solutions A peritoneal dialysis solution that is biochemically balanced to correct metabolic acidosis associated with chronic renal failure in a more physiological manner. The peritoneal dialysis solution has a physiological pH, e.g., pH of 7.0 to 7.4, and contains bicarbonat... | 03/14/2006 |
| 6998422 | Lipid peroxide-lowering compositions Compositions having excellent blood lipid peroxide lowering activity are provided. In particular, compositions for lowering lipid peroxides in the blood which contain pravastatin together with at least one substance selected from the group consisting of taurine, pan... | 02/14/2006 |
| 6982097 | Biocidal compositions and methods of using same This invention relates to biocidal compositions and methods of using same. Also provided is a process for the manufacturing of a biocidal composition in the form of a tablet and a method of using the biocidal compositions for the disinfection of water that may conta... | 01/03/2006 |
| 6974583 | Pantethinesulphonic acid and/or a salt thereof as a free-radical scavenger Pantethinesulphonic acid and/or a salt thereof as a free-radical scavenger. Prevent or combat the harmful effects of UV and/or pollution on the skin, loss of firmness and/or elasticity of the skin, etc. ... | 12/13/2005 |
| 6964969 | Composition and method for treating impaired or deteriorating neurological function A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radi... | 11/15/2005 |
| 6951890 | Preventing and/or treating cardiovascular disease and/or associated heart failure Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such a... | 10/04/2005 |
| 6916848 | Compounds for the treatment of metabolic disorders Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed. ... | 07/12/2005 |
| 6911473 | Detectable agent for wood treatment and method for its detection The present invention relates to a composition comprising an organic preservative acid and a UV-active indicator substance for preserving wood and for detection of the sufficient preservation of wood. ... | 06/28/2005 |
| 6906086 | Methods for inhibiting bone loss The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptab... | 06/14/2005 |
| 6903235 | Pharmaceutical-grade ferric citrate The present invention relates to pharmaceutical-grade ferric citrate. Pharmaceutical-grade ferric citrate contains a definite composition and a definite hydrate. The present invention also relates to a method using a solid—solid reaction to produce pharmaceutical-... | 06/07/2005 |
| 6887897 | Calcium glutarate supplement and phosphorus binder Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accord... | 05/03/2005 |
| 6881750 | Potassium taurate bicarbonate and ascorbate Compositions comprising potassium taurate bicarbonate complexes and/or potassium taurate ascorbate complexes are useful as pharmaceutical compositions and as dietary ingredients in nutritional supplements, medical foods, and other foods. In preferred embodiments, po... | 04/19/2005 |
| 6858750 | Use of fumaric acid derivatives for treating mitochondrial diseases The present invention relates to the use of individual fumaric acid derivatives or mixtures thereof for preparing a pharmaceutical composition for treating mitochondrial diseases, especially for treating Parkinson's syndrome, Alzheimer's disease, Chorea Huntington d... | 02/22/2005 |
| 6855734 | Glycine betaine and its use Pharmaceutical uses of glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation. ... | 02/15/2005 |
| 6835750 | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the admin... | 12/28/2004 |
| 6803057 | Hydrogen peroxide disinfectant with increased activity An acidic aqueous hydrogen peroxide solution is provided with improved disinfectant activity. Concentrated solutions preferably contain up to about 8 wt./wt. % H2O2 and as-used concentrations contain about 0.5% wt./wt. % H2O2. The solution also contains from 0.05 to... | 10/12/2004 |
